Syndax Pharmaceuticals stock analysis
Syndax Pharmaceuticals (1T3) Stock Price & Analysis
1T3 Stock Chart & Stats
- Day’s Range
- EUR 7.86 - EUR 7.86
- 52-Week Range
- EUR 7.86 - EUR 21.66
- Previous Close
- EUR 8.34
- Volume
- N/A
- Average Volume (3M)
- 235
- Market Cap
- EUR 749.61M
- Enterprise Value
- EUR 1.85B
- Total Cash (Recent Filing)
- EUR 427.10M
- Total Debt (Recent Filing)
- EUR 589.41M
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revuforj Commercial Momentum
Sustained Revuforj growth indicates expanding adoption rather than a single launch-related spike. Rising new-patient starts, prescriptions, account penetration, and repeat use support a broader commercial base that can compound revenue and strengthen the product’s position in targeted acute leukemia.
Market Leadership And Access
Dominant class share, broad formulary coverage, and adoption across large and community accounts create durable commercial advantages. These factors can reduce access friction, support physician familiarity, and help preserve Revuforj’s position as indications and patient populations expand.
Diversified Growth Pipeline
The company combines a growing marketed franchise with expansion opportunities in front-line disease, additional leukemia populations, chronic GVHD, lung cancer, and myelofibrosis. This breadth provides multiple paths to extend growth and reduces reliance on a single near-term clinical outcome.
Bears Say
Persistent Unprofitability
Despite higher revenue and very strong gross margin, Syndax remains far from breakeven. Continued operating losses can absorb the benefit of commercial growth, require sustained expense discipline, and delay the point at which the marketed portfolio can independently fund research and development.
Cash Burn And Funding Reliance
Large recurring cash outflows reduce financial flexibility while Syndax funds commercialization and several clinical programs. Although burn improved from prior years, continued negative free cash flow may require future financing or tighter capital allocation, potentially increasing dilution or limiting investment choices.
Leverage And Negative Equity
Higher debt combined with negative equity signals a materially weakened capital base and constrains resilience if operating losses persist. Leverage can increase financing pressure and reduce flexibility to support pipeline investment, commercial expansion, or unexpected development needs over the coming quarters.
Syndax Pharmaceuticals News
Syndax Updates Revumenib Study for Patients With Organ Impairment
Syndax Pharmaceuticals Inc. ($SNDX) announced an update on their ongoing clinical study. Study Overview: Syndax Pharmaceuticals is evaluating how the body processes revumenib in people with relapsed or treatment-resistant blood
1T3 FAQ
What was Syndax Pharmaceuticals’s price range in the past 12 months?
What is Syndax Pharmaceuticals’s market cap?
When is Syndax Pharmaceuticals’s upcoming earnings report date?
How were Syndax Pharmaceuticals’s earnings last quarter?
Is Syndax Pharmaceuticals overvalued?
Does Syndax Pharmaceuticals pay dividends?
What is Syndax Pharmaceuticals’s EPS estimate?
How many shares outstanding does Syndax Pharmaceuticals have?
What happened to Syndax Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Syndax Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Syndax Pharmaceuticals Stock Smart Score
Company Description
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael A. Metzger
- Employees
- 298
- Website
- www.syndax.com
- Address
- 730 Third Avenue, New York City, NY, 10017, US
Syndax Pharmaceuticals (1T3) Earnings & Revenues
1T3 Company Deck
1T3 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 82% year-over-year total revenue growth, sustained double-digit Revuforj growth, expanding patient starts and account adoption, rising Niktimvo revenue and collaboration income, a strong cash position, and multiple clinical and pipeline catalysts. The principal challenges were the temporary transplant-related treatment pauses, prior-quarter market volatility, active competition and delayed timing for certain clinical readouts. Highlights significantly outweighed the lowlights.
View all DE:1T3 earnings summaries1T3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 15 |
| Technical Analysis | 5 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |













